ArticleEye (London, England)2026
The role of pars plana vitrectomy in managing complications related to retinal focal nodular gliosis (vasoproliferative tumours).
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo assess the outcomes of pars plana vitrectomy (PPV) in patients with complications related to retinal focal nodular gliosis (FNGs), also known as vasoproliferative tumours. MATERIAL/SUBJECTS AND
methodsThis retrospective case series included 22 patients who underwent PPV for the management of FNG-related complications at Moorfields Eye Hospital between 2012 and 2024. We collected and analysed the patient demographics, clinical features and surgical outcomes.
resultsThe mean age was 50.59 years (SD 14.5) at presentation and 52.59 years (SD 13.9) at the time of surgery. The most common indications for surgery were epiretinal membrane (n = 9, 40.9%) and vitreous haemorrhage (n = 8, 36.4%). Fifteen eyes (68.2%) were treatment-naïve, while five (22.7%) had previously undergone ruthenium plaque radiotherapy. The median follow-up period was 34 months (IQR 6.0-62.2). The median preoperative visual acuity was 1.15 logMAR (IQR 0.67-2.40), which significantly improved to 0.4 logMAR (IQR 0.17-1.0) at the last follow-up visit (p < 0.01). Postoperative complications were not observed in 14 patients (63.6%), while cystoid macular oedema was the most common complication following vitrectomy (13.6%, n = 3). Three patients required FNG-related re-operation for rhegmatogenous retinal detachment, macular hole, and epiretinal membrane. All FNGs were inactive at the last follow-up visit. DISCUSSION: Vitreous haemorrhage and epiretinal membrane are the most common indications for surgery in patients with FNG. PPV demonstrates favourable functional and anatomic outcomes, though it is worth noting a 13.6% re-operation rate for complications. Significant visual improvement and effective tumour control are also recorded in the long-term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.